AbbVie Pinpoints US Humira Erosion At 37% In 2023

With adalimumab biosimilars now on market in the US, AbbVie said it expects sales erosion this year toward the lower end of its previous guidance, with pricing comprising the larger portion of the hit.

Biosimilar
With the first Humira biosimilar on the US market, AbbVie addressed investor concerns • Source: Shutterstock

Ten days after the first Humira biosimilar reached the US market, AbbVie Inc. is giving investors a definitive sense of what US revenue erosion will be for its top-seller in 2023 – 37% – with CEO Richard Gonzalez saying “the vast majority of that will be [from] price.”

Amgen, Inc. launched Amjevita, the first US Food and Drug Administration-approved biosimilar of adalimumab, on 31 January with two...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.